Ask AI
Optimizing MDS Care

CE / CME

An Update on Optimizing Care for Myelodysplastic Syndromes

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: November 22, 2023

Expiration: November 21, 2024

Activity

Progress
1
Course Completed

References

  1. Garcia-Manero G. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:1307-1325.
  2. Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data. Blood. 2022;140:1200-1228.
  3. Valent P, Orazi A, Steensma DP, et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017;8:73483-73500.
  4. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: myelodysplastic syndromes. v.2.2023. nccn.org. Accessed November 14, 2023.
  5. Xie Z, Zeidan AM. CHIPing away the progression potential of CHIP: a new reality in the making. Blood Rev. 2023;58:101001.
  6. Gurnari C, Xie Z, Zeidan AM. How I manage transplant ineligible patients with myelodysplastic neoplasms. Clin Hematol Int. 2023;5:8-20.
  7. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703-1719.
  8. Zeidan AM, Shallis RM, Wang R, et al. Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it. Blood Rev. 2019;34:1-15.
  9. Stahl M, Bewersdorf JP, Xie Z, et al. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Rev. 2023:101128.
  10. Brunner AM, Leitch HA, van de Loosdrecht AA, et al. Management of patients with lower-risk myelodysplastic syndromes. Blood Cancer J. 2022;12:166.
  11. Sekeres MA, Cutler C. How we treat higher-risk myelodysplastic syndromes. Blood. 2014;123:829-836.
  12. Bernard E, Tuechler H, Greenberg PL, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022;1:EVIDoa2200008. 
  13. Madanat YF, Xie Z, Zeidan AM. Advances in myelodysplastic syndromes: promising novel agents and combination strategies. Expert Rev Hematol. 2023;16:51-63.
  14. Zavras P, Sinanidis I, Tsakiroglu P, et al. Understanding the continuum between high-risk myelodysplastic syndrome and acute myeloid leukemia. Int J Mol Sci. 2023;24:5018.
  15. Ivosidinib [prescribing information]. Boston, MA: Servier Pharmaceuticals LLC; 2023.
  16. Luspatercept [prescribing information]. Summit, NJ: Celgene Corp, a Bristol Myers Squibb Company; 2023.
  17. Platzbecker U, Della Porta MG, Santini V, et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet. 2023;402:373-385.
  18. Bewersdorf JP, Xie Z, Zeidan AM. Novel approaches and future directions in myelodysplastic syndrome treatment. Cancer J. 2023;29:195-202.
  19. Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118:3765-3776.
  20. Santini V, Almeida A, Giagounidis A, et al. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J Clin Oncol. 2016;34:2988-2996.
  21. Lenalidomide [prescribing information]. Princeton, NJ: Bristol Myers Squibb Company; 2023.
  22. Stahl M, DeVeaux M, de Witte T, et al. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Adv. 2018;2:1765-1772.
  23. Sasaki K, Jabbour E, Montalban-Bravo G, et al. Low-dose decitabine versus low-dose azacitidine in lower-risk MDS. NEJM Evid. 2022;1:EVIDoa2200034.  
  24. Jabbour E, Short NJ, Montalban-Bravo G, et al. Randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower-risk MDS and MDS/NPN. Blood. 2017;130:1514-1522.
  25. Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382:140-151.
  26. Di Veroli A, De Bellis E, Rossi V, et al. Clinical use of ESAs in low-risk myelodysplastic syndromes. J Rare Dis Res Treat. 2017;2:41-44.
  27. Zeidan AM, Platzbecker U, Garcia-Manero G, et al. Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts. Blood. 2022;140:2170-2174.
  28. Garcia-Manero G, Platzbecker U, Santini V, et al. Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive transfusion-dependent patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2023;41(suppl 16):7003.
  29. Wang X, Hu CS, Petersen B, et al. Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells. Blood Adv. 2018;2:2378-2388.
  30. Steensma DP, Fenaux P, Van Eygen K, et al. Imetelstat achieves meaningful and durable transfusion independence in high transfusion–burden patients with lower-risk myelodysplastic syndromes in a phase II study. J Clin Oncol. 2021;39:48-56.
  31. Zeidan AM, Platzbecker U, Santini V, et al. IMerge: results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients with heavily transfusion dependent non-del(5q) lower-risk myelodysplastic syndromes relapsed/refractory to erythropoiesis stimulating agents. J Clin Oncol. 2023;41(suppl 16):7004.
  32. Zeidan AM, Long JB, Hall J, et al. Comparative effectiveness of azacitidine versus decitabine among older adults diagnosed with higher-risk myelodysplastic syndromes (HR-MDS). Blood. 2015;126:3285-3285.
  33. Zeidan AM, Sekeres MA, Garcia-Manero G, et al. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia. 2016;30:649-657.
  34. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223-232.
  35. Stempel JM, Xie Z, Bewersdorf JP, et al. Evolution of therapeutic benefit measurement criteria in myelodysplastic syndromes/neoplasms. Cancer J. 2023;29:203-211.
  36. Zeidan AM, Platzbecker U, Bewersdorf JP, et al. Consensus proposal for revised international working group 2023 response criteria for higher-risk myelodysplastic syndromes. Blood. 2023;141:2047-2061.
  37. Sekeres MA, Taylor J. Diagnosis and treatment of myelodysplastic syndromes: a review. JAMA. 2022;328:872-880.
  38. Nakamura R, Saber W, Martens MJ, et al. Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome. J Clin Oncol. 2021;39:3328-3339.
  39. Garcia-Manero G, McCloskey JK, Griffiths EA, et al. Oral decitabine/cedazuridine in patients with lower risk myelodysplastic syndrome: A longer-term follow-up from the Ascertain study. Blood. 2021;138:66.
  40. Savona MR, McCloskey JK, Griffiths EA, et al. Prolonged survival observed in 133 MDS patients treated with oral decitabine/cedazuridine. Presented at: 2021 International Congress on Myelodysplastic Syndromes; September 23-26, 2021. Abstract P48.
  41. Blum S, Tsilimidos G, Bresser H, et al. Role of Bcl-2 inhibition in myelodysplastic syndromes. Int J Cancer. 2023;152:1526-1535.
  42. Garcia JS, Wei AH, Jacoby MA, et al. Molecular responses are observed across mutational spectrum in treatment-naïve higher-risk myelodysplastic syndrome patients treated with venetoclax plus azacitidine. Blood. 2021;138:241.
  43. Zeidan AM, Borate U, Pollyea DA, et al. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. Am J Hematol. 2023;98:272-281.
  44. Zeidan AM, Garcia JS, Fenaux P, et al. Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-naive higher-risk myelodysplastic syndromes. J Clin Oncol. 2021;39(suppl 15):TPS7054.
  45. Zeidan AM, Boss I, Beach CL, et al. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. Blood Adv. 2022;6:2207-2218.
  46. Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020;20:173-185.
  47. Zeidan AM, Ando K, Rauzy O, et al. Primary results of STIMULUS-MDS1: a randomized, double-blind, placebo-controlled phase II study of TIM-3 inhibition with sabatolimab added to hypomethylating agents in adult patients with higher-risk myelodysplastic syndromes (MDS). Blood. 2022;140(suppl1):2063.
  48. Lee S, Mohan S, Knupp J, Chamoun K, et al. Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents. J Hematol Oncol. 2022;15:103.
  49. Bewersdorf JP, Xie Z, Bejar R, et al. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): proceedings from the 1st International Workshop on MDS (iwMDS) of the International Consortium for MDS (icMDS). Blood Rev. 2023;60:101072.